Eggleston Medscribe Minneapolis, MN - 55441

Eggleston Medscribe is categorized under Miscellaneous Personal Services (Unclassified) in Minneapolis, MN .

Eggleston Medscribe was established in 0, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Miscellaneous Personal Services (Unclassified) business, which does work in the B2C market, and is classified as a Miscellaneous Personal Services (Unclassified), under code number 8129904 by the NAICS.

If you are seeking more information, feel free to contact at the company’s single location by writing to 3501 Xenium Lane North Apartment 357, Minneapolis, Minnesota MN 55441 or by phoning (763) 450-3432. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Eggleston Medscribe
Address: 3501 Xenium Lane North Apartment 357, Minneapolis, Minnesota 55441
Phone Number: (763) 450-3432
Annual Revenue (USD): $100.000 to $499.999
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2C (Business to Consumer)
Business Category: Miscellaneous Personal Services (Unclassified)
SIC Code: 7299
NAICS Code: 8129904
Share This Business:

Eggleston Medscribe was started in 0 to provide professional Miscellaneous Personal Services (Unclassified) under the SIC code 7299 and NAICS code 8129904. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.

Feel free to contact for inquiries that concern Eggleston Medscribe by calling the company number (763) 450-3432, as your correspondence is most welcome. Additionally, the physical location of the single location of Eggleston Medscribe can be found at the coordinates 45.02062,-93.451515 as well as the street address 3501 Xenium Lane North Apartment 357 in Minneapolis, Minnesota 55441.

For its online presence, you may visit Eggleston Medscribe’s website at and engage with its social media outlets through on Twitter and on Facebook.